EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 NOMAD Increases Voyager Fleet Energy Storage by up to 56%, Bringing Eagle and Falcon to 2.025 MWh Boca Raton, Fla., July 8, 2026 - NOMAD Power Solutions, Inc. (“NOMAD” or the “Company”) (Nasdaq: NMAD), through its wholly owned subsidiary, Nomad Transportable Power Systems Inc., today announced the third-generation of its Voyager mobile energy storage series, headlined by a fleet-wide energy storage capacity increase. The third-generation upgrade raises standard usable storage on the Voyager Eagle and Falcon to 2.025 MWh each, and on the Voyager Hawk to 1.0 MWh, delivering more than 50% additional energy on every model without changing footprint, rated power output, or sub-one-hour deployment time. The increased capacity is standard on all new Voyager units going forward. The third-generation Voyager builds on NOMAD’s partnership with Octillion Power Systems, integrating its prismatic LFP pack architecture to reach higher energy density in the same transportable, semi-trailer form factor. It reflects NOMAD’s approach of continually improving the platform as battery technology advances, rather than tying customers to a single generatio…
Open exhibit ↗Current Report · Items 7.01, 9.01 · 8-K
NOMAD POWER SOLUTIONS, INC.
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On July 8, 2026, Nomad Power Solutions, Inc., (the “Company”), issued a press release announcing the capacity increase of its fleet-wide energy storage. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.…
Company context
We are a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. Our product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which are used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. We believe that inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. We are focusing on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity.
Recent company filings
- Regulation FD DisclosureOct 6, 2026
- Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesSep 30, 2026
- Financial Statements and ExhibitsSep 17, 2026
- 10-Q filingAug 14, 2026
- SCHEDULE 13G - filed by VANGUARD CAPITAL MANAGEMENT LLC regarding NOMAD POWER SOLUTIONS, INC.Jul 31, 2026